Player FM 앱으로 오프라인으로 전환하세요!
Ep. 247 Keynote 689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer with Dr. Adam Luginbuhl, Dr. Jennifer Johnson, Dr. Mihir Patel and Dr. Siddharth Sheth
Manage episode 518842964 series 3569300
When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.
---
SYNPOSIS
The doctors address the trial's practical implications, patient selection, case management, dealing with tumor progression, and the integration of multidisciplinary care. They also emphasize the importance of communication, real-world application of trial protocols, and the potential benefits and challenges of such therapies.
---
TIMESTAMPS
00:00 - Introduction
03:18 - Discussing the New Indication for Immunotherapy
11:42 - Challenges and Practical Implementation
22:48 - Managing Tumor Progression: A Case Study
28:07 - Exploring Treatment Options: Surgery vs. Chemotherapy
36:46 - Operational Challenges and Future Directions
43:58 - Concluding Thoughts and Future Directions
---
RESOURCES
Keynote 689
https://www.nejm.org/doi/full/10.1056/NEJMoa2415434
249 에피소드
Manage episode 518842964 series 3569300
When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.
---
SYNPOSIS
The doctors address the trial's practical implications, patient selection, case management, dealing with tumor progression, and the integration of multidisciplinary care. They also emphasize the importance of communication, real-world application of trial protocols, and the potential benefits and challenges of such therapies.
---
TIMESTAMPS
00:00 - Introduction
03:18 - Discussing the New Indication for Immunotherapy
11:42 - Challenges and Practical Implementation
22:48 - Managing Tumor Progression: A Case Study
28:07 - Exploring Treatment Options: Surgery vs. Chemotherapy
36:46 - Operational Challenges and Future Directions
43:58 - Concluding Thoughts and Future Directions
---
RESOURCES
Keynote 689
https://www.nejm.org/doi/full/10.1056/NEJMoa2415434
249 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.